Startseite › Plattenepithelkarzinom im Kopf-Hals-Bereich › Pennsylvania › Pittsburgh
Klinische Studien zu Plattenepithelkarzinom im Kopf-Hals-Bereich in Pittsburgh, PA
22 Studien zu Plattenepithelkarzinom im Kopf-Hals-Bereich suchen Teilnehmer an Standorten in und um Pittsburgh (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
Teilnehmer gesuchtPhase 3
- Allegheny General Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- und 7 weitere
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Teilnehmer gesuchtPhase 2/3
- Site #0103, Pittsburgh
- Site #0123, Pittsburgh
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Teilnehmer gesuchtPhase 1
- Exelixis Clinical Site #32, Pittsburgh
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Teilnehmer gesuchtPhase 3
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- und 4 weitere
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Teilnehmer gesuchtPhase 1
- Research Site, Pittsburgh
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Teilnehmer gesuchtPhase 2
- UPMC Hillman Cancer Center, Pittsburgh
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Teilnehmer gesuchtPhase 2
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Teilnehmer gesuchtPhase 2
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC-Saint Margaret, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- und 9 weitere
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Teilnehmer gesuchtPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Research Site, Pittsburgh
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
Teilnehmer gesuchtPhase 2/3
- UPMC-Magee Womens Hospital, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Teilnehmer gesuchtPhase 2
- UPMC-Saint Margaret, Pittsburgh
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
- UPMC-Shadyside Hospital, Pittsburgh
- und 5 weitere
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Teilnehmer gesuchtPhase 2
- UPMC Hillman Cancer Center, Pittsburgh
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Teilnehmer gesuchtPhase 1
- UPMC Hillman Cancer Ctr /ID# 225706, Pittsburgh
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
Teilnehmer gesuchtPhase 3
- GSK Investigational Site, Pittsburgh
Window of Opportunity in Preserving Laryngeal Function Trial
Teilnehmer gesuchtPhase 2
- UPMC Hillman Cancer, Pittsburgh
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Teilnehmer gesuchtPhase 3
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
A Study of VET3-TGI in Patients With Solid Tumors
Teilnehmer gesuchtPhase 1
- UPMC- Hillman Cancer Center, Pittsburgh
Use of SPY Imaging System to Minimize Fistulas After Hypopharyngeal Reconstruction
Teilnehmer gesuchtPhase 2
- UPMC, Pittsburgh
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Teilnehmer gesuchtPhase 1/2
- University of Pittsburgh, Pittsburgh
Plattenepithelkarzinom im Kopf-Hals-Bereich-Studien in anderen Städten
- Houston, TX47 Studien
- Los Angeles, CA42 Studien
- Boston, MA40 Studien
- New York City, NY39 Studien
- Nashville, TN39 Studien
- St. Louis, MO28 Studien
- Arlington, VA26 Studien
- Chicago, IL26 Studien
- Philadelphia, PA26 Studien
- Atlanta, GA24 Studien
- San Antonio, TX22 Studien
- New Haven, CT22 Studien
Weitere Studien in Pittsburgh
- Nichtkleinzelliges Lungenkarzinom48 Studien
- Krebs (alle Arten)41 Studien
- Brustkrebs39 Studien
- Kolorektales Karzinom32 Studien
- Metastasierender Krebs31 Studien
- Melanom31 Studien
- Eierstockkrebs30 Studien
- Endometriumkarzinom23 Studien
- Prostatakrebs23 Studien
- Lungenkrebs23 Studien
- Schlaganfall22 Studien
- Depression22 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.